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ABSTRACT – This study aimed to investigate the diagnostic accuracy of the Baptista Depression Scale adult and screening 
versions (EBADEP-A and EBADEP-screening) for discrimination of people with a major depressive episode (MDE) or 
major depressive disorder (MDD) and to compare discriminative capacities. Participants were 187 people, 52 patients, and 
135 non-clinical individuals. Results indicated sensitivity equal to 0.92 and specificity equal to 0.88 for EBADEP-A (cut-off 
= 54), and 0.96 and 0.82, respectively, for EBADEP-screening (cut-off = 17). Findings suggest equivalence between the 
two versions of EBADEP to discriminate people with MDE or MDD. Results indicate that the two versions can provide 
a correct diagnostic indicative for MDE and MDD.
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Acurácia Diagnóstica da Escala Baptista de Depressão:  
Versões Adulto e Triagem
RESUMO – O objetivo da presente investigação foi verificar a acurácia diagnóstica da Escala Baptista de Depressão 
adulto e triagem (EBADEP-A e EBADEP- triagem) para discriminação de pessoas com episódio depressivo maior (EDM) 
e/ou transtorno depressivo maior (TDM), e comparar suas capacidades discriminativas. Participaram 187 pessoas, 52 
pacientes e 135 do grupo não clínico. Os resultados indicaram sensibilidade igual a 0,92 e especificidade igual a 0,88 para 
a EBADEP-A (ponto de corte igual a 54), e 0,96 e 0,82, respectivamente, para a EBADEP-triagem (ponto de corte igual a 
17). Os achados sugerem equivalência entre as duas versões da EBADEP para discriminação de pessoas com EDM e/ou 
TDM. Os resultados indicam que as duas versões podem fornecer um indicativo diagnóstico correto para EDM e TDM.
PALAVRAS-CHAVE: psicopatologia, saúde mental, propriedades psicométricas, ponto de corte
Depressive disorders present the highest prevalence 
compared to other psychiatric disorders. According to the 
World Health Organization (WHO, 2017), 300 million 
people suffer from a depressive episode worldwide, 
representing 5% of the population. Besides, depressive 
disorders are related to disability and withdrawal from 
professional activities, representing about 12% of total 
leave from work, impacting the individual’s life and the 
organizational environment.
The etiology of depressive disorders is still complex 
to identify, arising from several factors, biological (e.g., 
genetics, hormonal dysregulation), psychological (e.g., self-
criticism, personality traits), and social (e.g., relationships, 
social acceptance; Fried & Neste, 2015). The combination 
of these factors is responsible for the onset, development, 
and remission of depressive symptoms (Durisko et al., 2015; 
Fried & Neste, 2015; Lichtenberg & Belmaker, 2010).
Within the category of depressive disorders, the Major 
Depressive Episode (MDE) represents the most classic 
condition of this group, and the Major Depressive Disorder 
(MDD). MDD can reach 16.2% of people worldwide 
(Kessler et al., 2003). For MDD configuration, recurrent 
depressive episodes must occur, that is, at least two 
depressive episodes. Depressive episodes correspond to the 
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presence of diagnostic criteria for MDE and/or MDD for 
at least two weeks. In the case of a first or single episode, 
MDE is characterized (APA, 2014).
Detection of MDE and MDD can be conducted following 
the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5; APA, 2014) and the International Classification 
of Diseases and Health-Related Problems (ICD-10; WHO, 
1996). In DSM-5, the individual must present at least one 
of the two symptoms considered central, namely, anhedonia 
or depressed mood. It is also necessary to manifest at least 
four more symptoms, which may be: loss or marked gain 
in weight, insomnia or hypersomnia, fatigue, agitation or 
psychomotor retardation, feeling of uselessness or excessive 
or inadequate guilt, decreased ability to think or concentrate 
and recurring thoughts of death. Besides, symptoms must 
be present for at least two intermittent weeks (APA, 2014).
In addition to the criteria reported in the manuals for 
the diagnosis of MDE and MDD, symptoms perceived by 
clinicians are presented by literature as relevant for the 
correct diagnosis of MDE and MDD (Goldberg, 2011; 
Lichtenberg & Belmaker, 2010). Specifically, the diagnostic 
criteria do not include some symptoms observed in clinical 
practice, like anguish, anxiety, social instability, irritability, 
hopelessness, and hypochondria (Beard et al., 2016; Beck 
et al., 1997; Fried et al., 2016). These characteristics make 
MDE and MDD heterogeneous diagnostic categories 
(Goldberg, 2011).
Some techniques and tools are employed to assist 
the professional in diagnosing MDE and MDD, such as 
interviews, observations, and scales. Concerning scales, 
these are generally based on the manuals’ diagnostic criteria 
for the development of items. However, some scales have 
also been designed considering the symptoms observed by 
clinicians, trying to encompass all the characteristics that 
configure MDE and MDD, and assist in the correct diagnosis 
of these conditions (Baptista, 2012; Beck et al., 1997; Fried, 
2016; Fried et al., 2016; Lichtenberg & Belmaker 2010).
The verification of a scale’s ability to assist in diagnosing 
a pathology is typically conducted in diagnostic accuracy 
studies. Diagnostic accuracy concerns the capability that an 
instrument, technique, or methodology has to discriminate 
groups, that is, how much an assessment tool is capable of 
identifying people with the condition and also discarding 
diagnosis for people without the condition (Bossuyt & 
Leeflang, 2008; Faraone & Tsuang, 1994; Parshall, 2013). 
These studies have clinical contributions, as they provide 
information that grant professionals greater security in 
decision making (Glasser, 2014).
The main diagnostic accuracy indicators are sensitivity, 
specificity, positive predictive value, negative predictive 
value, probability rates, and effectiveness test. Sensitivity 
refers to how well an instrument can correctly select a person 
with the pathology; specificity concerns how much a tool can 
correctly select a person who does not have the pathology; 
the positive predictive value refers to the probability that a 
positive result will be truly positive based on the prevalence 
of the investigated pathology; the negative predictive 
value refers to the likelihood of a negative result being 
truly negative based on the prevalence of the investigated 
pathology; the probability rates correspond to the probability 
of a person actually having the pathology; effectiveness 
rate refers to the instrument’s total ability to discriminate 
between individuals with pathology and individuals without 
pathology. Through these indicators, one can conclude about 
the instruments’ diagnostic capacity (Glasser, 2014; Lalkhen 
& McCluskey, 2008; Van Stralen et al., 2009).
Studies verified the diagnostic accuracy of instruments 
that assess depressive symptoms. For instance, Santos et al. 
(2013), in a study using the Patient Health Questionnaire-9 
(PHQ-9), found a sensitivity of 77.5% and specificity of 
86.7%, in a sample of 447 participants from the general 
population, 40 of which were diagnosed with MDD by the 
Mini International Neuropsychiatric Interview (MINI). 
Another study, using the Beck Depression Inventory-II 
(BDI-II), found sensitivity equal to 70% and specificity 
equal to 87% with a sample of 242 individuals from 
the general population from which possible individuals 
diagnosed with depression were extracted through the 
Structured Clinical Interview for the DSM-IV (Gomes-
Oliveira et al., 2012).
In Brazil, the Baptista Depression Scale (EBADEP-A; 
Baptista, 2012) was created to track depressive symptoms 
in adults. EBADEP-A is a self-report scale composed of 45 
items in pairs of antagonistic sentences at each end of the 
item to be answered in a four-point Likert format. Studies 
carried out using EBADEP-A observed evidence for its use 
and good psychometric properties (Baptista, 2012; Baptista 
et al., 2012; Bighetti et al., 2014; Carneiro & Baptista, 
2012; Souza et al., 2015). In addition to EBADEP-A, a 
screening version was developed, with 15 items on a 4-point 
Likert scale (Baptista & Carvalho, 2018). Shorter scales 
can provide benefits, such as lower spending and faster 
assessments, and are useful tools mainly in public health 
services and primary care (Bolsoni & Zuardi, 2015).
Two studies were conducted aiming to verify the 
diagnostic accuracy of EBADEP-A. The first study 
encompassed 1,676 individuals, observing sensitivity equal 
to 77.5% and specificity equal to 87.5 (Baptista, 2012); 
and another study with 40 depressive patients (MDE or 
MDD) and 40 people from the general population and 
without a diagnosis, observing sensitivity equal to 97.5% 
and specificity equal to 90.5% (Baptista & Carvalho, 2018). 
In this same study (Baptista & Carvalho, 2018), the short 
version of EBADEP-A (EBADEP-screening) was also 
used, which obtained 95% sensitivity and 87.5% specificity. 
Screening tests should have greater sensitivity in comparison 
to specificity, making it possible to identify all individuals 
with the condition (Germans et al., 2012).
Despite satisfactory findings with EBADEP-A and 
EBADEP-screening, studies aiming to verify these scales’ 
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diagnostic accuracy are still scarce. Considering that MDE 
and MDD have a high prevalence in the population, that 
the correct diagnosis can improve a patient’s prognosis, 
and that EBADEP-A and EBADEP-screening can be 
useful tools to diagnose these psychopathologies, our study 
aimed to verify the diagnostic accuracy of EBADEP-A and 
EBADEP- screening in the discrimination of people with 
MDD and MDE. Besides, we sought to verify which of the 
two versions of EBADEP is the most discriminative. In 
order to achieve the proposed objectives, we replicated the 
procedures used by Baptista and Carvalho (2018), although 
in a larger sample. We created four hypotheses: H1) the 
clinical group should present higher means in EBADEP-A 
and EBADEP-screening (Baptista, 2012); H2) EBADEP-A 
and EBADEP-screening should show an area under the 
curve (ROC curve) > 0.80, considered good (Bewick et al., 
2004; Baptista & Carvalho, 2018 Hosmer & Lemeshow, 
2000); H3) EBADEP-A and EBADEP-screening should 
have greater sensitivity and less specificity to select a greater 
number of cases (Germans et al., 2012); H4) EBADEP-A 
should have greater discriminative power compared to 
EBADEP-screening (Baptista & Carvalho, 2018).
METHOD
Participants
Our sample was composed of 187 individuals divided 
into clinical and non-clinical groups. The clinical group 
consisted of 52 participants, mostly female (92.3%) aged 
between 18 and 62 years old (M = 35.71 SD = 11.54), who 
were being treated for MDE or MDD in a Psychosocial Care 
Center (CAPS) and the Family Health Strategy (ESF). As 
inclusion criteria, the patient should present a diagnosis of 
MDE or MDD by a psychiatrist. Therefore, the gold standard 
for the clinical sample was the diagnosis by a psychiatrist.
The non-clinical group was composed of 135 individuals, 
college students, the majority (72.2%) was female, aged 
between 18 and 51 (M = 23.8 and SD = 6.49). Participants 
in this group reported never having undergone psychiatric 
and psychological treatment, not using medication for any 
psychopathology, and had no symptoms of MDE or MDD. 
The Beck Depression Inventory (BDI) was used to confirm 
this psychopathology absence in the group.
Instruments
Baptista Depression Scale Adult Version (EBADEP-A; 
Baptista,2012)
This instrument was designed and standardized in 
Brazil to track symptoms of depression in psychiatric and 
non-psychiatric samples. The scale was developed based 
on the DSM-IV-TR, ICD-10, the Cognitive Model, and 
the Behavioral Theory. This one-dimension scale consists 
of 45 items disposed on a semantic-differential format, 
containing two contrasting statements each. A rating scale is 
used to measure if the participant agrees more with the first 
statement, the second, or with both at the same magnitude. 
Studies have revealed good psychometric properties for the 
scale (Baptista, 2012; Baptista & Carvalho, 2018; Bighetti 
et al., 2014).
Baptista Depression Scale - Screening Version 
(EBADEP- Screening)
EBADEP-screening was developed based on the adult 
version of EBADEP (EBADEP-A; Baptista, 2012). This 
scale aims to assess the symptoms of depression and is 
composed of 15 items selected based on the main symptoms 
of psychiatric manuals, such as sad mood, anhedonia, 
guilt, fatigue, concentration, suicidal ideation, and sleep. 
In the study conducted by Baptista e Carvalho (2018), the 
EBADEP-screening was able to discriminate 40 patients 
diagnosed with depression by SCID-I from 40 people 
without depression, with sensitivity equal to 95.0 and 
specificity of 87.5. In this study, the internal consistency 
reliability of EBADEP-screening was equal to 0.78.
Beck Depression Inventory (BDI; Beck et al., 1961)
The BDI is a self-report scale composed of 21 items, with 
a 4-point Likert scale. The cutoffs are the following: 0 to 11 
= minimum, 12 to 19 = mild, 20 to 35 = moderate, and 36 
to 63 = severe. Studies indicate good psychometric qualities 
of this scale (Beck et al., 1988; Paranhos et al., 2010; Wang 
& Gorenstein, 2013). We employed the cutoff indicated by 
Kendall et al. (1987), suggesting that individuals with scores 
above 20 points should be classified as mild depressive.
Procedures
Our research was received by the University of São 
Francisco ethics committee and approved. Data collection 
with the group of depressives was performed with people 
designated by the referred treatment centers who had 
a confirmed diagnosis of depression. Participants were 
informed about the data collection procedures. The 
applications, including EBADEP-A, were carried out in an 
appropriate service room, individually.
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The non-clinical group was composed of people without 
a diagnosis of depression and a self-reported psychiatric 
history. This group responded to EBADEP-A and BDI. 
BDI was used as a gold standard to verify the absence of 
depressive conditions in this group. The exclusion criterion 
was presenting indicators of depression in the BDI.
We highlight that EBADEP-screening scores were 
calculated later, extracting the items that make up this 
version of EBADEP-A.
Data Analysis
We organized data in an electronic spreadsheet and later 
exported it to the statistical program SPSS version 21 and 
the statistical program Medcalc. The t-test was employed 
to compare the mean score of depressive and non-clinical 
groups, and the Cohen’s d (Cohen, 1992) indicator was 
used to verify the differences’ magnitude. We used the 
ROC (Receiver Operating Characteristic) curve analysis 
to investigate the best cutoff and calculate the sensitivity, 
specificity, true predictive value, negative predictive value, 
positive probability rates, negative probability rate, and the 
efficiency test of the scales. In order to calculate the positive 
and negative predictive values, we used the formula proposed 
by Streiner (2003) for samples without prevalence were 
used. Finally, to verify the equivalence of EBADEP-A and 
EBADEP-screening, the intraclass correlation coefficient 
(ICC) and binary logistic regression were calculated.
RESULTS
Table 1 presents the t-test results to compare the means 
between the groups in EBADEP-A and EBADEP-screening.
The clinical group showed a higher mean than the 
non-clinical group in the total score of EBADEP-A and 
EBADEP-screening. We observed big difference between 
the groups. In Figure 1 and Table 2, we present the ROC 
curve results, including diagnostic accuracy indicators.
The area under the ROC curve was 0.96 (CI = 0.925 and 
0.985; p = 0.001) for EBADEP-A and 0.95 (CI = 0.90 and 
0.98; p = 0.001) for EBADEP-screening.
The best cutoff was 54, with better sensitivity indicators 
than the cutoff 59, as suggested by the EBADEP-A manual. 
Screening scales should be highly sensitive, indicating that 
the instrument has little chance of false negative.
We use Streiner’s formula (2003) for samples without 
prevalence information to calculate the positive and 
negative predictive values. The values were 0.91 and 
0.92, respectively, indicating that an individual with a 
positive result on EBADEP-A has 91% chance of having 
depression, while a person with a negative result on 
EBADEP-A has 92% chance of not having depression. The 
positive and negative probability rates were calculated. 
The values were 7.90 and 0.09, respectively, showing 
moderate ability to identify who has MDE or MDD and 
high ability to identify who does not have these conditions. 
The effectiveness test showed that EBADEP-A correctly 
identified 89% of the total cases (people with and without 
a diagnosis).
Table 1
Mean comparison between depressive and non-clinical groups.









Note. - = non-clinical group; + = clinical group. 
Table 2
Diagnostic accuracy indicators for EBADEP-A and EBADEP-screening
CO Ss Sp +PV -PV +PR -PR ET
EBADEP-A
54 0,92 0,88 0,91 0,92 7,90 0,09 0,89
59 0,84 0,91 0,86 0,91 9,66 0,17 0,89
EBADEP-screening 17 0,96 0,82 0,96 0,81 5,45 0,05 0,87
Note. CO: cutoff; Ss = sensitivity; Sp = specificity; +PV = positive predictive value; -PV = negative predictive value; +PR = positive probability rates; 
-PR = negative probability rates; TE = effectiveness test.
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The results indicated that, for EBADEP-screening, the 
cutoff 17 is the most appropriate. As in EBADEP-A, the 
screening version also showed higher sensitivity values. 
The values suggest that 96% of individuals positive for 
depression on EBADP-screening have a diagnosis (MDE or 
MDD), and 81% of people negative on EBADEP-screening 
did not have a diagnosis for the same conditions. The positive 
probability rate was 5.45, and the negative probability rate 
was 0.05, indicating moderate ability to identify who has 
MDE or MDD and a high ability to identify individuals 
without these conditions. The effectiveness test showed 
that the EBADEP-screening correctly identified 87% of 
the cases.
The cutoff of 59 for EBADEP-A correctly identified 
45 patients with MDE or MDD and 123 non-patients. In 
contrast, the cutoff 54 indicated by our study’s results, 
correctly identified 47 patients and 125 non-patients. 
EBADEP-screening was able to identify 50 patients and 
110 non-patients correctly.
We employed the ICC and logistic regression analysis 
to investigate the equivalence between EBADEP-A and 
EBADEP-screening. The ICC was 0.88 (p <0.01), and in 
logistic regression, the r2nagelkerke was 0.70 for EBADEP-A, 
and r2nagelkerke was 0.63 for EBADEP-screening.
DISCUSSION
Diagnostic accuracy indicators provide information to 
the professional, whichhelps decide whether a person is 
diagnosed with a particular condition. Besides, diagnostic 
accuracy information may indicate a correct prognosis for a 
case (Glasser, 2014). The present study aimed to verify the 
diagnostic accuracy of EBADEP-A and EBADEP-screening 
in the discrimination of people with and without MDE and 
MDD and verify the equivalence between the two versions of 
the scale. Our hypotheses were partially confirmed, with the 
clinical group presenting higher means in both versions of 
EBADEP (H1). The AUC was above 0.90 (H2), in addition 
to both versions of the scale showing greater sensitivity 
in comparison to specificity (H3). The hypothesis that 
EBADEP-A would have a better discriminative capacity 
than screening (H4) was refuted.
The depressive group presented higher mean than the 
non-clinical group in EBADEP-A and EBADEP-screening, 
with differences of strong magnitude. Similar results with 
EBADEP-A previously indicated this scale’s capacity to 
identify people with MDE or MDD (Baptista & Gomes, 
2011). The findings with EBADEP-screening also exhibited 
the ability to separate the groups, even slightly higher than 
EBADEP-A, which may indicate that the screening version 
provides an assessment close to the full version. Bolsoni 
and Zuardi (2015) emphasize the usefulness of brief scales 
mainly for primary health care use. The full version of the 
scale can generate more diagnostic information and be 
recommended for use in contexts where the professional 
is available for further investigation, while the screening 
version can be used in contexts of faster assessments such 
as screening in public health services.
The two versions of EBADEP presented an excellent 
result in the AUC (Bewick et al., 2004; Hajian -Tilaki, 2013; 
Hosmer & Lemeshow, 2000; Obuchowski, 2000), which 
refers to the instrument’s general accuracy capacity (Glasser, 
2014), being slightly higher in EBADEP-A. These data 
indicate both versions havegood general capacity to identify 
people with MDE or MDD. The cutoffs suggested in this 
study (54 for EBADEP-A and 17 for EBADEP-screening) 
were shown to correctly identify the largest number of cases 
of MDE and MDD.
As for the ability to identify true positive and negative 
cases, the findings indicate that EBADEP-A and EBADEP-
screening present superior results when compared with other 
tools such as BDI-I (Cunha, 2016), BDI-II (Gomes et al., 
2012), and PHQ-9 (Santos et al., 2013). The positive and 
negative predictive values were calculated based on Streiner 
(2003) for samples with no prevalence and indicated that 
the results of EBADEP-A and EBADEP-screening provide 
correct information for diagnostic decision-making. Both 
versions showed good capacity to identify people with or 
without depression, demonstrating the usefulness of these 
scales in the clinical context.
Our findings indicate that the two versions of EBADEP 
are equivalent. Moreover, the results suggest that the 
screening version, with a smaller number of items, has a 
Figure 1. AUC of EBADEP-A and EBADEP-screening
Note. AUCebadep-a = 0,96 (IC = 0,925 - 0,985; p = 0,001); AUCebadep-screening = 
0,95 (IC = 0,90 - 0,98; p = 0,001)
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capacity similar to the full version of EBADEP-A. This 
finding is in line with what was observed by Baptista and 
Carvalho (2018), who also found equivalence between the 
versions. The results of the diagnostic accuracy indicators, 
in general, also suggest the use of the screening version as 
this version obtained similar results to the full version, using 
fewer items and requiring less administration time.
Our findings indicate that the two versions of EBADEP 
provide essential information to assist clinicians in making 
decisions on the presence of MDE or MDD, specifically for 
screening purposes. However, the results must be weighed 
in light of the main methodological limitations of the 
study. The restricted sample size may have decreased the 
variability of the observed responses; the unequal number 
of men and women may have impacted the results; we 
did not administer other tests to assess MDE and MDD, 
making it impossible to compare the versions of EBADEP 
with external measures.
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